<DOC>
	<DOCNO>NCT01712893</DOCNO>
	<brief_summary>The present study randomize open-label -phase III study aim compare efficacy safety adjuvant chemotherapy simultaneous sequential application Zoladex 2-3 year ≤ 45 year old premenopausal hormone receptor-positive breast cancer .</brief_summary>
	<brief_title>Simultaneous Versus Sequential Use Adjuvant Chemotherapy GnRHa Treating ER+ , Premenopausal Breast Cancer</brief_title>
	<detailed_description>Data show ovarian suppression therapy may protect ovarian function premenopausal patient receive chemotherapy breast cancer . However still controversial issue . Sequential use GnRHa ( Zoladex ) ovarian suppression treatment chemotherapy establish effective endocrine therapy ER positive premenopausal breast cancer . The present study randomize open-label phase III study aim observe efficacy safety adjuvant chemotherapy simultaneous combination Zoladex 2-3years chemotherapy compare sequential schedule ≤ 45 year old premenopausal hormone receptor-positive breast cancer patient .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Taxane</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>1. female 2 . Primary invasive breast cancer pathologically approve core needle open biopsy 3 . Patients must undergo standard surgery primary breast cancer show follow : mastectomy breast conservation surgery follow whole breast radiation axillary dissection sentinel node biopsy 4 . Need adjuvant chemotherapy surgery 5 . Patients take neochemotherapy eligible 6 . Patients synchronous bilateral cancer eligible condition If one side IDC side DCIS , IDC side ER and/or PR positive phenotype IF two side IDC , must ER and/or PR positive phenotype time 7 . Hormone receptor positive ( ≥＋ ) define detect ER PR expression time eligible . The situation PR positive ER negative eligible , 8 . Based study objective , patient require premenopausal define menstruate actively less 6 month since last menstrual period ( LMP ) , patient young 40 year age become amenorrheic 1 year serum free E2、FSH LH level premenopausal ( accord reference value local center ) . previous hysterectomy one ovaries leave intact eligible serum free E2、FSH LH level premenopausal ( accord reference value local center ) . 9. patient must ECOG performance status 0 1 ( 0fully active , able carry predisease performance without restriction , 1restricted physical strenuous actively ambulatory ) 10. leucocyte count must ≥ 3.0*10^9/L platelet count must ≥ 100*10^9/L 11 . AST/SGOT ALT/AGPT must &lt; 3 time ULN 12. serum creatinine must &lt; 2 time ULN 13. pregnancy test negative willing contraception treatment period 1. patient metastatic malignant tumor 2. previous history asynchronous bilateral breast cancer 3. previous malignancy past 5 year , except treat curative intent , carcinoma situ cervix , squamous carcinoma skin basal cell carcinoma skin 4. nonmalignant systemic disease interfere long time follow 5. history medical ovarian ablation therapy 6. severe live dysfunction , Child－Pugh grade C 7 . Severe renal dysfunction 8 . Occult breast cancer 9. severe heart dysfunction , heart functional classification Class III</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>adjuvant therapy</keyword>
	<keyword>Ovarian suppression</keyword>
</DOC>